SCHEMBL3006571

SCHEMBL3006571

Cc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4ccc(F)cc4F)CC3)n2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR6 P46095 1/20 0.39
LMNA P02545 1/20 0.38
NAAA Q02083 4/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
DNM1L O00429 4/20 0.35
MAPK1 P28482 1/20 0.35
CTSS P25774 3/20 0.35
TP53 P04637 1/20 0.35
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34
KCNH2 Q12809 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP1A2 P05177 1/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
CYP2C9 P11712 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015637 0.93 LMNA (0.38) GPR6LMNANAAASMN1; SMN2NPC1
SCHEMBL3010134 0.93 GPR6 (0.39) GPR6LMNANAAASMN1; SMN2NPC1
SCHEMBL3018853 0.91 CTSS (0.45) GPR6NAAASMN1; SMN2NPC1RAB9A
SCHEMBL3014144 0.91 LMNA (0.39) GPR6LMNANAAAMAPK1CTSS
SCHEMBL3015457 0.91 GPR6 (0.38) GPR6LMNANAAASMN1; SMN2NPC1
SCHEMBL3011191 0.91 NAAA (0.36) LMNANAAASMN1; SMN2NPC1RAB9A
SCHEMBL3010789 0.91 HTR2A (0.42) GPR6LMNANAAASMN1; SMN2NPC1
SCHEMBL3010780 0.91 NAAA (0.41) GPR6LMNANAAASMN1; SMN2NPC1
SCHEMBL3011732 0.90 GPR6 (0.42) GPR6LMNANAAASMN1; SMN2NPC1
SCHEMBL3010968 0.90 GPR6 (0.38) GPR6LMNANAAASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA GPR6 4245/4885LMNA 80/4885NAAA 3229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.